ATE348632T1 - Prion protein peptide und deren verwendung - Google Patents

Prion protein peptide und deren verwendung

Info

Publication number
ATE348632T1
ATE348632T1 AT00941708T AT00941708T ATE348632T1 AT E348632 T1 ATE348632 T1 AT E348632T1 AT 00941708 T AT00941708 T AT 00941708T AT 00941708 T AT00941708 T AT 00941708T AT E348632 T1 ATE348632 T1 AT E348632T1
Authority
AT
Austria
Prior art keywords
prion protein
protein peptides
prp
therapeutic
antibodies specific
Prior art date
Application number
AT00941708T
Other languages
English (en)
Inventor
Neil R Cashman
Eustache Paramithiotis
Jacek Slon-Usakiewicz
Ashkan Haghighat
Marc Pinard
Trebor Lawton
Original Assignee
Caprion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22492135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE348632(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Caprion Pharmaceuticals Inc filed Critical Caprion Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE348632T1 publication Critical patent/ATE348632T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00941708T 1999-06-23 2000-06-23 Prion protein peptide und deren verwendung ATE348632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14063499P 1999-06-23 1999-06-23

Publications (1)

Publication Number Publication Date
ATE348632T1 true ATE348632T1 (de) 2007-01-15

Family

ID=22492135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941708T ATE348632T1 (de) 1999-06-23 2000-06-23 Prion protein peptide und deren verwendung

Country Status (12)

Country Link
EP (1) EP1194164B8 (de)
JP (1) JP2003521477A (de)
CN (1) CN1370078A (de)
AT (1) ATE348632T1 (de)
AU (1) AU783484B2 (de)
CA (1) CA2377648A1 (de)
DE (1) DE60032486T2 (de)
ES (1) ES2278617T3 (de)
HK (1) HK1048955A1 (de)
MX (1) MXPA01013186A (de)
NZ (1) NZ516240A (de)
WO (1) WO2000078344A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041807B1 (en) 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
JP2004501626A (ja) * 2000-06-26 2004-01-22 ウニヴェルジテート　チューリッヒ 血清および血漿中に見出されるプリオン結合活性を有する因子
US7303907B2 (en) 2001-01-08 2007-12-04 Health Protection Agency Degradation and detection of TSE infectivity
GB2376071A (en) * 2001-05-31 2002-12-04 Mini Agriculture & Fisheries Method for typing a TSE strain
GB2379737A (en) * 2001-09-05 2003-03-19 Univ Geneve Diagnostic method for spongiform encephalopathy disease
EP1442300A2 (de) * 2001-11-09 2004-08-04 King's College London Diagnose von entmarkungs- oder spongiformen krankheiten
WO2003059386A2 (en) * 2002-01-18 2003-07-24 Cytos Biotechnology Ag Prion protein carrier-conjugates
US7939641B2 (en) * 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
EP1382971A1 (de) * 2002-07-17 2004-01-21 Pepscan Systems B.V. Nachweis von Prion Erkrankung
US20040072236A1 (en) * 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
EP2211181A1 (de) * 2002-10-30 2010-07-28 Proteome Sciences Plc Methoden um übertragbare Spongiforme Enzephalopathien zu diagnostizieren
GB0227886D0 (en) * 2002-11-29 2003-01-08 Medical Res Council Prion inhibition
CA2836951C (en) * 2002-12-03 2017-01-10 North Carolina State University Prion protein ligands and methods of use
US20040192887A1 (en) * 2003-03-25 2004-09-30 Ralph Zahn PH-dependent polypeptide aggregation and its use
CN1297663C (zh) * 2003-05-07 2007-01-31 中国科学院微生物研究所 一类重组基因产生的朊蛋白（PrPC）融合变构体及其用途
NZ580256A (en) 2003-08-13 2011-07-29 Novartis Vaccines & Diagnostic Prion-specific peptide reagents comprising the sequence KKRPKPGG
EP1668369B1 (de) * 2003-08-20 2016-01-06 ProMIS Neurosciences Inc. Epitopschutztest und verfahren zum nachweis von proteinkonformationen
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
US7482172B2 (en) 2005-09-19 2009-01-27 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
AU2005209592B2 (en) 2004-09-30 2012-07-12 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
EP1931695B1 (de) 2005-09-09 2013-04-10 Novartis AG Prionspezifische Peptoidreagentien
US7794692B2 (en) 2005-12-02 2010-09-14 Amorfix Life Sciences Ltd. Methods and compositions for detecting amyotrophic lateral sclerosis
US7887803B2 (en) 2005-12-02 2011-02-15 Amorfix Life Sciences Methods and compositions to treat misfolded-SOD1 mediated diseases
DK2514823T3 (en) 2006-03-03 2018-07-23 Promis Neurosciences Inc Methods and compositions for treating and detecting failed SOD1-mediated diseases
US7601506B2 (en) 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
BRPI0910456A2 (pt) 2008-04-25 2016-07-19 Univ Saskatchewan petídeos imunogênicos priônicos e suas repetições
EP2128618A1 (de) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. Verfahren zur Kontrolle der Präsenz von pathogenen Wirkstoffen in biologischen Flüssigkeiten durch nanostrukturierte Stoffe
US20100233176A1 (en) * 2008-10-06 2010-09-16 Cashman Neil R Methods and systems for predicting misfolded protein epitopes
US9110024B2 (en) 2009-03-25 2015-08-18 Los Alamos National Security, Llc Fiber optical asssembly for fluorescence spectrometry
AU2010229864A1 (en) * 2009-03-25 2011-10-27 Los Alamos National Security, Llc Rapid antemortem detection of infectious agents
TWI419711B (zh) * 2010-07-27 2013-12-21 Univ Nat Changhua Education Tyrosinase polypeptide inhibitor
CN102492018A (zh) * 2010-07-27 2012-06-13 萧乃文 酪氨酸酶多肽抑制剂
EP2666020A1 (de) * 2011-01-18 2013-11-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Verfahren für die amplifikation und den nachweis von prionen
JP6430373B2 (ja) * 2012-06-12 2018-11-28 プロミス、ニューロサイエンシズ、インコーポレイテッドＰｒｏｍｉｓ Ｎｅｕｒｏｓｃｉｅｎｃｅｓ Ｉｎｃ． ミスフォールドプリオンタンパク質を標的とする抗体および複合体
US9809620B2 (en) 2013-04-30 2017-11-07 University Of Saskatchewan Prion disease-specific epitopes and methods of use thereof
CN108409865A (zh) * 2018-01-19 2018-08-17 鄞州出入境检验检疫局综合技术服务中心 特异性双酚a羊多克隆抗体及其应用
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ246059A (en) * 1991-12-03 1995-08-28 Proteus Molecular Design Synthetic polypeptides with at least one antigenic site of a prion protein, methods of their use and manufacture, antibodies thereto, compositions and kits
AU4376093A (en) * 1992-05-15 1993-12-13 Instituto Nazionale Neurologico C. Besta Soluble prion polypeptides, and methods for detecting and purifying thereof
EP1416280A3 (de) * 1995-09-14 2005-08-10 The Regents of the University of California Antikörper spezifisch für natives PrPsc
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
EP0861900A1 (de) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunologischer Nachweis von Prionen
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

Also Published As

Publication number Publication date
CN1370078A (zh) 2002-09-18
WO2000078344A1 (en) 2000-12-28
WO2000078344A8 (en) 2001-11-15
JP2003521477A (ja) 2003-07-15
NZ516240A (en) 2005-11-25
EP1194164A1 (de) 2002-04-10
DE60032486T2 (de) 2007-08-16
EP1194164B8 (de) 2007-03-21
DE60032486D1 (de) 2007-02-01
AU5637500A (en) 2001-01-09
CA2377648A1 (en) 2000-12-28
AU783484B2 (en) 2005-11-03
EP1194164B1 (de) 2006-12-20
HK1048955A1 (zh) 2003-04-25
ES2278617T3 (es) 2007-08-16
MXPA01013186A (es) 2002-08-12
EP1194164A4 (de) 2004-09-08

Similar Documents

Publication Publication Date Title
DE60032486D1 (de) Prion protein peptide und deren verwendung
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE60239931D1 (de) Kombinationstherapie
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
ATE385806T1 (de) Fusionsproteine
ATE455561T1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EP1200124A4 (de) Immunglobulin fusionsproteine
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
BR9707819A (pt) Imunogenos peptidicos
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
DE69725754D1 (de) Eingekapselte Antikörper-produzierende Zellen
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE528392T1 (de) Neues protein und dessen dns
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties